P21 Cancer Research Results

P21, P21/CDKN1A: Click to Expand ⟱
Source:
Type: Proapototic
cyclin-dependent kinase inhibitor p21 (also known as p21 WAF1/Cip1) promotes cell cycle arrest in response to many stimuli.
P21 is a cyclin-dependent kinase inhibitor that plays a crucial role in regulating the cell cycle. It is encoded by the CDKN1A gene and is a key player in the cellular response to stress, including DNA damage.
P21 is often considered a tumor suppressor because its expression is upregulated in response to p53 activation, a well-known tumor suppressor protein. When DNA damage occurs, p53 can activate the transcription of the CDKN1A gene, leading to increased levels of P21, which helps prevent the proliferation of damaged cells.
In many cancers, the p53 pathway is disrupted, leading to decreased levels of P21. p21 is a apoptotic marker protein.
Cell cycle arrest gene p21
Field Suggested Entry
Target CDKN1A / p21 / p21Cip1/Waf1
Full Name Cyclin-dependent kinase inhibitor 1A
Target Class CIP/KIP-family cyclin-dependent kinase inhibitor
Main Binding Partners CDK2, CDK1, CDK4/6, cyclin complexes, PCNA
Primary Biology p53-mediated cell-cycle arrest, DNA damage response, senescence, differentiation, CDK inhibition, RB/E2F pathway suppression, apoptosis regulation
Cancer Relevance High but context-dependent: p21 can suppress tumor growth through cell-cycle arrest and senescence, but can also support apoptosis resistance, senescent-cell survival, and therapy resistance in some tumors
AD Relevance Medium: indirect relevance through neuronal cell-cycle re-entry, senescence, p53 stress signaling, and aging-related cell-cycle dysregulation
Therapeutic Direction Context-dependent. Restore/activate p21 for tumor-suppressive arrest where appropriate; inhibit or bypass p21 where it promotes apoptosis resistance, senescent-cell survival, or treatment resistance.


Scientific Papers found: Click to Expand⟱
4786- Lyco,    Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3
TumCP↓, TumCCA↑, cl‑PARP↑, ERK↑, cycD1/CCND1↓, P21↓, p‑Akt↓, mTOR↓, BAX↑, AntiCan↑, Risk↓,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
4792- Lyco,    A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy
- Review, Var, NA
*AntiCan↑, *antiOx↑, Inflam↓, Wnt↓, β-catenin/ZEB1↓, *ROS↓, BioAv↑, ROS↓, Risk↓, PGE2↓, COX2↓, p‑ERK↓, P21↑, MMP7↓, MMP9↓, ChemoSen↑, eff↑,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
5252- MAG,    Insights on the Multifunctional Activities of Magnolol
- Review, Var, NA
BioAv↓, *Inflam↓, *Bacteria↓, *antiOx↑, *neuroP↑, *cardioP↑, CYP1A1↓, *PPARγ↑, *NF-kB↓, *COX2↓, *iNOS↓, *ROS↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, P21↑, TumCG↓, TumCMig↓, TumCI↓, Ki-67↓, PCNA↓, MMP2↓, MMP9↓, MMP7↓, DNAdam↑, MMP↓, TumCP↓, selectivity↑, PI3K↓, Akt↓, H2O2↓, Hif1a↓, *BDNF↑, *NRF2↑, *AChE↑,
4518- MAG,  Cisplatin,    Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells
- in-vitro, GC, MKN45
ChemoSen↑, tumCV↓, BAX↑, Bcl-2↓, P21↑, P53↑, MMP9↓,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
4536- MAG,    Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis
- in-vitro, Liver, HepG2 - in-vivo, CRC, COLO205
AntiCan↑, selectivity↑, TumCCA↑, P21↑, Apoptosis↑,
4537- MAG,    Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action
- in-vivo, Melanoma, NA - in-vitro, Melanoma, A431
*cl‑Casp8↑, *PARP↑, *P21↑, tumCV↓, TumCP↓, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK4↓, CDC2↓, P21↑, Apoptosis↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
2255- MF,    Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress
- in-vitro, Nor, SkMC
*HSP70/HSPA5↑, *Apoptosis↓, *Inflam↓, *Trx↓, *PONs↓, *SOD2↓, *TumCG↑, *Diff↑, *HIF2a↑, *Cyt‑c↑, P21↑,
487- MF,    Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway
- in-vitro, NMSC, HaCaT
ATM↑, Chk2↑, P21↑, TumCCA↑,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
1311- NarG,  Rad,    Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis
- in-vitro, Lung, H23
tumCV↓, ROS↑, Casp3↑, p‑Akt↓, Akt↓, MMP2↓, P21↓,
1797- NarG,    Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway
- in-vitro, BC, MDA-MB-231
TumCG↓, β-catenin/ZEB1↓, AntiTum↑, Apoptosis↑, TumCCA↑, P21↑, survivin↓,
1015- NarG,    Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells
- in-vitro, Cerv, SiHa - in-vitro, Cerv, HeLa - in-vitro, Cerv, C33A
ER Stress↑, p‑eIF2α↑, CHOP↑, PARP1↑, Casp3↑, β-catenin/ZEB1↓, GSK‐3β↓, p‑β-catenin/ZEB1↓, p‑GSK‐3β↓, TumCCA↑, P21↑, p27↑,
6486- Nimb,    Nimbolide: promising agent for prevention and treatment of chronic diseases
- Review, Var, NA - Review, AD, NA
*other↝, *Inflam↓, AntiCan↑, *Bacteria↓, *AntiViral↑, *neuroP↑, *hepatoP↑, *ROS?, *NRF2↑, *HO-1↑, *TLR4↓, *NF-kB↓, *AChE↓, *Aβ↓, *GSK‐3β↓, *LDL↓, *DNAdam↓, *lipid-P↓, *antiOx↑, *SOD1↑, *GSH↑, *IL6↓, *IL1β↓, *STAT3↓, *GPx↑, *Catalase↑, *MDA↓, *AntiDiabetic↑, *HDL↓, *MCP1↓, *VEGF↓, *MMP9↓, *GutMicro↑, TumCP↓, TumCCA↑, TumCMig↓, NF-kB↓, ROS↑, PI3K↓, Akt↓, mTOR↓, ERK↓, EMT↓, TumMeta↓, ChemoSen↑, eff↑, selectivity↑, CDK4↓, CDK6↓, Wnt↓, β-catenin/ZEB1↓, STAT3↓, MMP2↓, Sp1/3/4↓, AP-1↓, P21↑, *AntiArt↑, *IL23↓, *IL17↓, *IFN-γ↓, *HSP70/HSPA5↓,
4630- OLE,    Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles
- in-vitro, BC, NA
Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Vim↓, Slug↓, E-cadherin↑, CSCs↓, P21↑, survivin↝, OCT4↑, Nanog↑, SOX4↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
2069- PB,    Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes
- in-vitro, Tong, NA
TumCG↓, ROS↑, P21↑, CycB/CCNB1↓, cDC2↓, CDC25↓, eff↓, TumCCA↑, Apoptosis↑,
2026- PB,    Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
- Trial, GBM, NA
Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
2035- PB,    Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease
- in-vitro, Nor, glial - in-vivo, NA, NA
*ROS↓, *Inflam↑, *P21↓, *antiOx↑, *GSH↑, *NF-kB↓, *neuroP↑, *HDAC↓, *iNOS↓, *TNF-α↓, *IL1β↓, *LDL↓, ROS↓,
2045- PB,    Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line
- in-vitro, GBM, LN229 - in-vitro, GBM, LN-18
HDAC↓, TumCG↓, TumCCA↑, P21↑, Bcl-2↓, Bcl-xL↓, BioAv↑,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
1676- PBG,    Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies
- Review, Var, NA
ROS↑, MMP↓, Bcl-2↓, eff↑, tumCV↓, TumCCA↑, angioG↓, PAK1↓, HDAC1↓, HDAC2↓, P53↑, PCNA↓, cycD1/CCND1↓, cycE/CCNE↓, P21?, BAX↑, cl‑Casp3↑, cl‑PARP↑, ChemoSen↑,
1661- PBG,    Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways
- Review, Var, NA
JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,
1664- PBG,    Anticancer Activity of Propolis and Its Compounds
- Review, Var, NA
Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1/CCNA1↓, CycB/CCNB1↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1/CCND1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
2430- PBG,    The cytotoxic effects of propolis on breast cancer cells involve PI3K/Akt and ERK1/2 pathways, mitochondrial membrane potential, and reactive oxygen species generation
- in-vitro, BC, MDA-MB-231
TumCP↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eff↓, MMP↓, LDH↑, ATP↓, Ca+2↑,
3257- PBG,    The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review
- Review, Var, NA
CDK4↓, CDK6↓, pRB↓, ROS↓, TumCCA↑, P21↑, PI3K↓, Akt↓, EMT↓, E-cadherin↑, Vim↓, *COX2↓, *MPO↓, *MDA↓, *TNF-α↓, *IL6↓, *Catalase↑, *SOD↑, *AST↓, *ALAT↓, *IL1β↓, *IL10↓, *GPx↓, *TLR4↓, *Sepsis↓, *IFN-γ↑, *GSH↑, *NRF2↑, *α-SMA↓, *TGF-β↓, *IL5↓, *IL6↓, *IL8↓, *PGE2↓, *NF-kB↓, *MMP9↓,
4947- PEITC,    Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G0/G1   Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death
- in-vitro, Oral, HSC3
AntiCan↑, chemoPv↑, TumCG↓, Apoptosis↑, TumCCA↑, P53↑, P21↑, BAX↑, BID↑, Bcl-2↓, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑,
4948- PEITC,    Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo
- vitro+vivo, Oral, CAL27 - vitro+vivo, Oral, FaDu - vitro+vivo, Oral, SCC4 - vitro+vivo, Oral, SCC9
TumCD↑, TumCG↓, OS↑, ROS↑, P53↑, P21↑, TumCCA↑, Ki-67↓,
4963- PEITC,    Sensory Acceptable Equivalent Doses of β - Phenylethyl isothiocyanate (PEITC) Induce Cell Cycle Arrest and Retard Growth of p53 Mutated Oral Cancer In Vitro and In Vivo
- vitro+vivo, Oral, CAL27 - vitro+vivo, Oral, FaDu - vitro+vivo, Oral, SCC4 - vitro+vivo, Oral, SCC9
Dose↝, selectivity↑, TumCG↓, OS↑, ROS↑, P53↑, P21↑, TumCCA↑, Ki-67↓,
4924- PEITC,    Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial
- Trial, Oral, NA
QoL↑, P53↑, OS↑, Cyt‑c↝, other↝, ROS↑, selectivity↑, P21↑, TumCCA↑, Dose↝, BioAv↑, Weight↑, chemoP↑,
4940- PEITC,    Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G 0/G 1 Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death
- in-vitro, Oral, HSC3
TumCCA↑, Apoptosis↑, BAX↑, BID↑, Bcl-2↓, MMP↓, Cyt‑c↑, AIF↑, tumCV↓, ROS↑, Ca+2↑, CDC25↓, CDK6↓, cycD1/CCND1↓, CDK2↓, cycE/CCNE↓, P53↑, p27↑, P21↑, Casp9↑, Casp3↑, GRP78/BiP↑,
1942- PL,    Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines
- in-vitro, BC, MCF-7
ROS↑, SOD1↑, Trx1↓, Catalase↓, PrxII↓, ROS↑, GADD45A↑, P21↑, DNAdam↑, TumCCA↑,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2957- PL,    Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCP↓, TumCMig↓, TumCCA↑, ROS↑, H2O2↑, GSH↓, IKKα↓, NF-kB↓, P21↑, eff↓,
5162- PLB,    Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells
- vitro+vivo, Melanoma, A172
TumCG↓, TumCCA↑, Apoptosis↑, P21↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDC2↓, CDC25↑, Bax:Bcl2↑, Casp9↑, ROS↑, JNK↑, ERK↑, eff↓,
5161- PLB,    Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells
- in-vitro, SCC, SCC25
TumCCA↑, Apoptosis↑, TumAuto↑, Bcl-2↓, Bcl-xL↓, BAX↑, PI3K↓, Akt↓, mTOR↓, GSK‐3β↓, MAPK↓, ROS↑, eff↓, CDC2↓, CycB/CCNB1↓, P21↑, p27↑, P53↑, Casp9↑, Casp3↑,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP↑,
36- QC,    Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
P53↑, P21↑, BAX↑, Casp3↑, Casp7↑, TumCCA↑, ROS↑, TumCCA↑, Apoptosis↑,
84- QC,    Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression
- in-vitro, Pca, PC3
P21↑, cDC2↓, CDK1↓, CycB/CCNB1↓, Casp3↑, Bcl-2↓, Bcl-xL↓, BAX↑, pRB↓, TumCCA↑, Apoptosis↑,
100- QC,    Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓, TumCCA↑, chemoPv↑,
913- QC,    Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression
- in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-435
TumCP↓, TumCCA↑, DNAdam↑, Chk2↑, CycB/CCNB1↓, CDK1↓, tumCV↓, p‑RB1↓, P21↑,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,

Showing Research Papers: 151 to 200 of 259
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 259

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Catalase↓, 2,   Catalase↑, 1,   CYP1A1↓, 1,   GPx↑, 2,   GSH↓, 3,   GSH↑, 1,   H2O2↓, 1,   H2O2↑, 1,   HO-1↑, 3,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 1,   MDA↑, 1,   NOX4↑, 1,   NQO1↑, 1,   NRF2↑, 3,   Prx4↑, 1,   PrxII↓, 1,   ROS↓, 4,   ROS↑, 33,   ROS⇅, 2,   SIRT3↓, 1,   SOD↑, 2,   SOD1↑, 2,   SOD2↓, 1,   SOD2↑, 1,   Trx1↓, 1,   TrxR↓, 2,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 3,   ATP↓, 2,   BCR↓, 1,   CDC16↓, 1,   CDC2↓, 3,   CDC25↓, 2,   CDC25↑, 1,   EGF↓, 1,   ETC↓, 1,   MMP↓, 12,   mtDam↑, 2,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   CAIX↑, 1,   cMyc↓, 5,   FASN↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 6,   lactateProd↓, 1,   LDH↓, 3,   LDH↑, 1,   LDHA↓, 2,   LDL↓, 1,   PFK↓, 3,   PKM2↓, 3,   PPARγ↑, 3,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 15,   p‑Akt↓, 4,   Apoptosis?, 1,   Apoptosis↑, 17,   ASK1↑, 1,   BAD↑, 1,   Bak↑, 1,   BAX↓, 2,   BAX↑, 18,   Bax:Bcl2↑, 1,   Bcl-2↓, 15,   Bcl-xL↓, 3,   BID↑, 2,   BIM↑, 1,   Casp3↓, 2,   Casp3↑, 17,   cl‑Casp3↑, 2,   Casp7↑, 3,   Casp8↑, 1,   cl‑Casp8↑, 2,   Casp9↑, 10,   CBP↑, 1,   cFLIP↓, 1,   Chk2↑, 2,   Cyt‑c↑, 6,   Cyt‑c↝, 2,   DR5↓, 1,   DR5↑, 1,   hTERT/TERT↓, 2,   iNOS↑, 1,   JNK↓, 1,   JNK↑, 3,   MAPK↓, 5,   MAPK↑, 1,   Mcl-1↓, 1,   MDM2↓, 1,   p27↑, 12,   p38↓, 1,   p‑p38↑, 1,   PUMA↑, 1,   survivin↓, 6,   survivin↝, 1,   Telomerase↓, 1,   TRAIL↑, 1,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

CDC7↓, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 4,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

BowelM↑, 1,   ChrMod↑, 1,   H3↓, 1,   miR-21↓, 1,   other?, 1,   other↝, 2,   pRB↓, 2,   tumCV↓, 8,  

Protein Folding & ER Stress ⓘ

CHOP↑, 6,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↓, 1,   GRP78/BiP↑, 3,   HSP27↑, 1,   PERK↑, 1,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

ATM↑, 1,   BRCA1↑, 1,   CUL4B↑, 1,   DNAdam↑, 5,   DNArepair↓, 1,   DNArepair↑, 1,   GADD45A↑, 1,   P53↑, 19,   PARP↑, 2,   cl‑PARP↑, 4,   PARP1↑, 1,   PCNA↓, 6,   TP53↓, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 5,   p‑CDK1↓, 1,   CDK2↓, 9,   CDK4↓, 10,   cycA1/CCNA1↓, 6,   CycB/CCNB1↓, 13,   cycD1/CCND1↓, 14,   CycD3↓, 1,   cycE/CCNE↓, 6,   cycF↓, 1,   E2Fs↓, 1,   P21?, 1,   P21↓, 5,   P21↑, 43,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 2,   TumCCA↓, 1,   TumCCA↑, 39,  

Proliferation, Differentiation & Cell State ⓘ

CD24↓, 1,   CD44↓, 1,   cDC2↓, 3,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 1,   EMT↓, 4,   EP300↑, 1,   ERK↓, 4,   ERK↑, 3,   p‑ERK↓, 2,   FOXO3↓, 2,   p‑FOXO3↓, 1,   GSK‐3β↓, 4,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   HDAC1↓, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   IGFBP3↑, 1,   mTOR↓, 10,   Nanog↓, 1,   Nanog↑, 1,   NF2↑, 1,   OCT4↓, 1,   OCT4↑, 1,   P70S6K↓, 1,   PI3K↓, 10,   PTEN↓, 1,   PTEN↑, 3,   RAS↓, 1,   Shh↓, 1,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 8,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 10,   TumCG↑, 1,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 2,   Ca+2↑, 5,   i-Ca+2↑, 1,   CDK4/6↓, 1,   CLDN2↓, 1,   E-cadherin↑, 4,   FAK↓, 2,   Ki-67↓, 4,   MMP13↓, 1,   MMP2↓, 6,   MMP7↓, 3,   MMP9↓, 8,   MMP9↑, 1,   MMPs↓, 2,   MSH2↑, 1,   N-cadherin↓, 1,   PAK1↓, 1,   PDGF↓, 2,   Slug↓, 2,   SMAD4↑, 1,   Snail↓, 1,   SOX4↑, 2,   TIMP1↓, 1,   TIMP1↑, 1,   Treg lymp↓, 1,   TSC1↑, 1,   TumCI↓, 5,   TumCMig↓, 6,   TumCP↓, 14,   TumMeta↓, 9,   TumMeta↑, 1,   Twist↓, 3,   Vim↓, 4,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 5,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 8,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 2,   eNOS↑, 1,   Hif1a↓, 6,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 8,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 2,   COX2↓, 5,   COX2↑, 1,   CXCR4↓, 1,   DCells↑, 1,   FOXP3↓, 1,   ICAM-1↓, 1,   Igs↑, 1,   IKKα↓, 2,   IL10↓, 2,   IL10↑, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 5,   IL8↓, 2,   Imm↑, 1,   Inflam↓, 3,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 12,   NK cell↑, 2,   p65↓, 2,   PGE2↓, 2,   PSA↓, 1,   PSA∅, 1,   T-Cell↑, 1,   Th1 response↑, 1,   TLR4↓, 2,   TNF-α↓, 2,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 5,   ER(estro)↓, 1,   GR↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 5,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 15,   Dose?, 1,   Dose↑, 1,   Dose↝, 5,   Dose∅, 3,   eff↓, 6,   eff↑, 21,   Half-Life↝, 2,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 8,   selectivity↑, 13,  

Clinical Biomarkers ⓘ

AR↓, 1,   BRCA1↑, 1,   EGFR↓, 2,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 5,   Ki-67↓, 4,   LDH↓, 3,   LDH↑, 1,   PSA↓, 1,   PSA∅, 1,   TP53↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 10,   AntiTum↑, 1,   Appetite↑, 1,   breath↑, 1,   cardioP↑, 1,   chemoP↑, 2,   chemoPv↑, 2,   ChemoSideEff↓, 1,   hepatoP↑, 1,   OS↑, 7,   OS⇅, 1,   Pain↓, 2,   QoL↑, 3,   radioP↑, 2,   Risk↓, 2,   Sleep↑, 1,   Strength↑, 2,   TGFβR1↑, 1,   toxicity↓, 2,   TumW↓, 1,   Weight↑, 2,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 345

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 4,   GPx↓, 1,   GPx↑, 2,   GSH↑, 7,   HDL↓, 1,   HO-1↑, 1,   lipid-P↓, 3,   MDA↓, 4,   MPO↓, 1,   NRF2↑, 5,   ROS?, 1,   ROS↓, 6,   SOD↑, 3,   SOD1↑, 1,   SOD2↓, 1,   Trx↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 1,   FASN↓, 1,   LDL↓, 2,   PONs↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   cl‑Casp8↑, 1,   Cyt‑c↑, 1,   iNOS↓, 2,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   P53↓, 1,   PARP↑, 1,  

Cell Cycle & Senescence ⓘ

P21↓, 2,   P21↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   mTOR↓, 1,   STAT3↓, 1,   TumCG↑, 1,  

Migration ⓘ

AntiAg↑, 2,   MMP9↓, 2,   TGF-β↓, 1,   α-SMA↓, 1,   β-Endo↑, 1,  

Angiogenesis & Vasculature ⓘ

HIF2a↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL10↓, 1,   IL17↓, 1,   IL1β↓, 3,   IL23↓, 1,   IL5↓, 1,   IL6↓, 4,   IL8↓, 2,   Inflam↓, 7,   Inflam↑, 1,   MCP1↓, 1,   NF-kB↓, 4,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,   AChE↓, 1,   AChE↑, 1,   BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   GutMicro↑, 1,   IL6↓, 4,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 3,   chemoP↑, 1,   hepatoP↑, 2,   neuroP↑, 4,   OS↑, 1,   Risk↓, 1,  

Infection & Microbiome ⓘ

AntiViral↑, 1,   Bacteria↓, 2,   Sepsis↓, 1,  
Total Targets: 90

Scientific Paper Hit Count for: P21, P21/CDKN1A
19 Thymoquinone
13 Curcumin
12 Apigenin (mainly Parsley)
11 Sulforaphane (mainly Broccoli)
8 Silver-NanoParticles
8 EGCG (Epigallocatechin Gallate)
8 Quercetin
7 Fisetin
7 Lycopene
7 Propolis -bee glue
7 Resveratrol
6 Eugenol
5 Berberine
5 Magnolol
5 Phenylbutyrate
5 Phenethyl isothiocyanate
5 Piperlongumine
5 Urolithin
4 Allicin (mainly Garlic)
4 Cisplatin
4 Biochanin A
4 Beta-Caryophyllene
4 Boswellia (frankincense)
4 Cucurbitacin
4 Ellagic acid
4 Ursolic acid
4 Emodin
4 Honokiol
4 Shikonin
3 Gemcitabine (Gemzar)
3 Baicalein
3 Capsaicin
3 Luteolin
3 Magnetic Fields
3 Naringin
3 salinomycin
3 Silymarin (Milk Thistle) silibinin
2 Alpha-Lipoic-Acid
2 Anethole/trans-Anethole
2 Ashwagandha(Withaferin A)
2 Astaxanthin
2 Berbamine
2 Betulinic acid
2 Caffeic acid
2 Carnosic acid
2 Carvacrol
2 Thymol-Thymus vulgaris
2 Chlorogenic acid
2 Crocetin
2 diet Methionine-Restricted Diet
2 Gallic acid
2 Garcinol
2 HydroxyTyrosol
2 Oleuropein
2 Plumbagin
2 Rosmarinic acid
1 5-fluorouracil
1 Coenzyme Q10
1 Astragalus
1 Camptothecin
1 Acetyl-l-carnitine
1 Andrographis
1 Fennel Oil/Foeniculum vulgare
1 Artemisinin
1 Atorvastatin
1 epirubicin
1 Bufalin/Huachansu
1 Boron
1 brusatol
1 Bruteridin(bergamot juice)
1 Chrysin
1 D-limonene
1 Docetaxel
1 Dandelion Root
1 Butyrate
1 Cinnamon
1 Ferulic acid
1 Fenbendazole
1 Gambogic Acid
1 Genistein (soy isoflavone)
1 Hydroxycinnamic-acid
1 Inositol
1 Juglone
1 Linalool
1 Melatonin
1 Magnetic Field Rotating
1 Radiotherapy/Radiation
1 Nimbolide
1 acetazolamide
1 Aflavin-3,3′-digallate
1 doxorubicin
1 Oxaliplatin
1 Vitamin C (Ascorbic Acid)
1 Magnesium
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:234  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page